^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Undisclosed ovarian cancer vaccine

    i
    Other names: Undisclosed ovarian cancer vaccine
    Associations

    News

    Trials
    Company:
    Anixa Biosci, Cleveland Clinic, National Cancer Institute
    Drug class:
    Immunostimulant, AMHR2-ED modulator
    Related drugs:
    Associations

    News

    Trials
    over2years
    Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas. (PubMed, Clin Exp Vaccine Res)
    These results were compared favorably with results obtained using CFA as an adjuvant in the AMHR2-ED vaccine. Our data indicate that the AMHR2-ED vaccine formulated with AddaVax may be used in human clinical trials and thereby serve as a novel and effective way to control human EOC.
    Preclinical • Journal
    |
    AMHR2 (Anti-Mullerian Hormone Receptor Type 2)
    |
    Undisclosed ovarian cancer vaccine